3月26日 - ** 券商 Stifel 开始覆盖药物开发商 Palvella Therapeutics PVLA.O，给予 "买入 "评级，目标价 45 美元。
** 新PT较该股上次收盘价上涨65
** Stifel认为PVLA有潜力建立一个罕见皮肤病治疗组合，"这些治疗组合的总价值可达数十亿美元"。
** Stifel 指出，该公司的凝胶 QTORIN 优化了皮肤深层的给药效果，患者耐受性高。
** 包括本交易日的走势在内，PVLA的股价今年以来上涨了一倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.